Gleevec/Glivec

Novartis lifts 2013 guidance on delay to Diovan generics

in at $315m, a rise of 38 per cent thanks to success in switching patients from Novartis' older therapy Glivec (imatinib).

Intellectual property threats in the BRIC markets

The recent upholding of the Indian patent office's rejection of Novartis' Glivec patent application is the latest in a series of actions including the compulsory licence of Nexavar and initiation

Pfizer faces NICE rejection for cancer drug Bosulif

Sir Andrew Dillon, NICE's chief executive, pointed out that the organisation had already recommended Novartis' Glivec (imatinib) and Tasigna (nilotinib) for different stages of CML, and that limited NHS resources

Ariad gets EU green light for leukaemia drug Iclusig

It can also be used in patients who are intolerant to Tasigna and Sprycel but are unsuitable for subsequent treatment with Novartis' Glivec (imatinib), as well as in CML patients who ... In the ALL indication, the Commission gave a green light for Iclusig

Merck wins injunction against Januvia generics in India

Earlier this year Novartis failed in a bid to secure protection for its Glivec (imatinib) cancer drug in India's Supreme Court, and there have also been knockbacks in recent months

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]